SequelSEC

Revolution Medicines, Inc. RVMD

Biological Products, (No Diagnostic Substances) · CIK 0001628171 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$1.18B
Fiscal year ended 2025-12-31
Free cash flow
-$913.73M
Fiscal year ended 2025-12-31

Revolution Medicines, Inc. (RVMD) reported revenue of $0 and net income of -$1.13B for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from Revolution Medicines, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Revolution Medicines, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$0$0$11.58M$35.38M$29.39M$42.98M$50.04M$20.16M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$1.18B-$689.52M-$487.18M-$258.28M-$188.01M-$110.70M-$54.12M-$40.33M
Net income-$1.13B-$600.09M-$436.37M-$248.70M-$187.09M-$108.16M-$47.66M-$41.79M
Research & development$987.33M$592.22M$423.14M$253.07M$186.95M$132.25M$91.76M$51.08M
Weighted-average diluted sharesshares 190.13Mshares 167.74Mshares 113.15Mshares 80.63Mshares 72.81Mshares 54.87MUnavailableUnavailable
Pretax income-$1.13B-$600.85M-$439.89M-$249.12M-$187.09M-$108.53M-$52.04M-$41.79M
Income tax expense$0-$753.00K-$3.52M-$420.00K$0-$371.00K-$4.37MUnavailable
Diluted EPS$-5.95$-3.58$-3.86$-3.08$-2.57$-2.01UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$195.04M$97.30M$75.62M$40.59M$30.45M$21.43M$12.41M$9.41M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Revolution Medicines, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$383.74M$543.06M$696.15M$161.41M$108.50M$104.27M$16.66M$69.59M
Total assets$2.35B$2.56B$2.06B$811.93M$737.99M$567.40M$220.53MUnavailable
Current assets$2.08B$2.33B$1.88B$660.18M$589.77M$454.12M$133.98MUnavailable
Total liabilities$723.21M$293.10M$235.51M$126.74M$135.42M$92.72M$67.99MUnavailable
Current liabilities$290.42M$163.91M$143.85M$61.98M$60.35M$47.18M$43.05MUnavailable
Total equity incl. NCI$1.63B$2.27B$1.83B$685.19M$602.57M$474.68M-$152.57M-$108.42M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$305.11MUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$14.61M$14.61M$14.61M$14.61M$14.61M$14.61M$14.61MUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$64.62M$54.43M$61.79M$21.31M$14.06M$12.61M$11.40MUnavailable

Cash flow

Revolution Medicines, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$897.74M-$557.44M-$350.57M-$224.40M-$147.18M-$100.06M-$49.62M$1.21M
Capital expenditures$15.99M$10.31M$7.73M$10.82M$6.53M$2.93M$2.59M$1.50M
Investing cash flow$118.06M-$554.39M-$342.60M-$24.12M-$142.12M-$234.23M-$101.97M-$1.34M
Financing cash flow$621.52M$959.41M$1.23B$301.43M$294.18M$422.78M$98.66M$60.85M
Net change in cash-$158.16M-$152.42M$536.03M$52.92M$4.88M$88.48M-$52.93M$60.72M
Stock-based compensation$118.39M$79.20M$61.77M$31.20M$20.72M$8.89M$3.16M$855.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable$0UnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$7.78M$6.56M$5.04M$3.97M$3.10M$2.61M$2.27M$1.57M

Derived

Revolution Medicines, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow-$913.73M-$567.74M-$358.30M-$235.22M-$153.71M-$103.00M-$52.20M-$286.00K
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailable-4207.1%-730.0%-639.7%-257.5%-108.2%-200.0%
FCF marginUnavailableUnavailable-3094.1%-664.8%-523.0%-239.6%-104.3%-1.4%
SBC / revenueUnavailableUnavailable533.4%88.2%70.5%20.7%6.3%4.2%
Current ratio7.14x14.20x13.06x10.65x9.77x9.63x3.11xUnavailable
Revenue YoY growthUnavailable-100.0%-67.3%20.4%-31.6%-14.1%148.2%Unavailable
Net marginUnavailableUnavailable-3768.3%-703.0%-636.6%-251.6%-95.2%-207.2%
R&D / revenueUnavailableUnavailable3654.1%715.3%636.1%307.7%183.4%253.3%
CapEx / revenueUnavailableUnavailable66.7%30.6%22.2%6.8%5.2%7.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RVMD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.